Malaria - Pipeline Review, H2 2012

Global Markets Direct, September 2012, Pages: 311

Malaria – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Malaria - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Malaria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malaria. Malaria - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Malaria.
- A review of the Malaria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Malaria pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Malaria.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Malaria pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 8
List of Figures 10
Introduction 11
REPORT COVERAGE 11
Malaria Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Malaria 13
Malaria Therapeutics under Development by Companies 15
Malaria Therapeutics under Investigation by Universities/Institutes 20
Late Stage Products 24
Comparative Analysis 24
Mid Clinical Stage Products 25
Comparative Analysis 25
Early Clinical Stage Products 26
Comparative Analysis 26
Discovery and Pre-Clinical Stage Products 27
Comparative Analysis 27
Malaria Therapeutics – Products under Development by Companies 28
Malaria Therapeutics – Products under Investigation by Universities/Institutes 32
Companies Involved in Malaria Therapeutics Development 38
Sanofi-Aventis 38
GlaxoSmithKline plc 39
Inovio Biomedical Corporation 40
GenVec, Inc. 41
Merck & Co., Inc. 42
Eastland Medical Systems Limited 43
Novartis AG 44
Actelion Ltd 45
Pfizer Inc. 46
Ranbaxy Laboratories Limited 47
Aduro BioTech 48
CEL-SCI Corporation 49
Crucell N.V. 50
Mymetics Corporation 51
Cleveland BioLabs, Inc. 52
Patrys Limited 53
Alnylam Pharmaceuticals, Inc 54
IPCA Laboratories Limited 55
Lipoxen PLC 56
Raptor Pharmaceuticals Corp. 57
PolyMedix, Inc. 58
Affitech A/S 59
Colby Pharmaceutical Company 60
Avanti Therapeutics 61
Bharat Biotech International Limited 62
Jenrin Discovery, Inc. 63
Mucosis B.V. 64
Anacor Pharmaceuticals, Inc. 65
Telormedix SA 66
Dilafor AB 67
Okairos 68
Sanaria Inc. 69
NovaLead Pharma Pvt. Ltd. 70
Acetylon Pharmaceuticals, Inc. 71
Etubics Corporation 72
iBio, Inc. 73
PepTcell Limited 74
Genocea Biosciences, Inc. 75
PALUMED S.A. 76
Sigma-Tau Pharmaceuticals, Inc. 77
Selecta Biosciences, Inc. 78
Pfenex Inc. 79
VLP Biotech, Inc. 80
Jomaa Pharma GmbH 81
Malaria – Therapeutics Assessment 82
Assessment by Monotherapy Products 82
Assessment by Combination Products 83
Assessment by Route of Administration 84
Assessment by Molecule Type 86
Drug Profiles 89
SAR-97276 - Drug Profile 89
ferroquine - Drug Profile 90
Malaria Vaccine - Drug Profile 91
tafenoquine - Drug Profile 93
PMX-30024 - Drug Profile 95
artemether - Drug Profile 96
CEL-1000 - Drug Profile 97
artesunate - Drug Profile 100
Pyramax - Drug Profile 101
OZ-439 - Drug Profile 103
210-infectious disease abs - Drug Profile 105
MK-4815 - Drug Profile 106
P218 DHFR - Drug Profile 107
Falcipain - Drug Profile 108
Queensland Natural Products Project - Drug Profile 109
VLD-571 - Drug Profile 110
BCX-4945 - Drug Profile 111
Drug targeting dihydroorotate dehydrogenase - Drug Profile 112
Synriam - Drug Profile 113
Drug targeting dihydroorotate dehydrogenase - Drug Profile 114
novel liver stage antimalarials - Drug Profile 115
JD-3000 Series - Drug Profile 116
CST-102 - Drug Profile 117
Malarial Vaccine - Drug Profile 118
trioxaquine - Drug Profile 119
EP-1300 - Drug Profile 120
Malaria Vaccine - Drug Profile 121
Vaccine For Mosquito-Borne Disease - Drug Profile 122
AERAS-Capsid - Drug Profile 123
Malaria Research Program - Drug Profile 124
PfSPZ Vaccine - Drug Profile 125
Atovaquone-Proguanil + Rosiglitazone - Drug Profile 127
Malaria Vaccine Programme - Drug Profile 128
Sulphadoxine + Pyrimethamine + Mefloquine + Chlorproguanil + Dapsone - Drug Profile 129
Artesunate + Mefloquine - Drug Profile 131
Azithromycin + Artesunate - Drug Profile 132
Amodiaquine + Artesunate - Drug Profile 134
Coartem - Drug Profile 135
Amodiaquine + Artesunate - Drug Profile 137
Artemether + Lumefantrine - Drug Profile 138
Amodiaquine + Sulfadoxine + Pyrimethamine - Drug Profile 140
Artekin - Drug Profile 142
diethyltoluamide - Drug Profile 144
chloroquine - Drug Profile 145
Chloroquine + Primaquine - Drug Profile 146
primaquine [INN] - Drug Profile 147
Plasmodium Vivax Irradiated Sporozoites - Drug Profile 148
artemether - Drug Profile 149
Zithromax + Chloroquine - Drug Profile 150
PEV-3 - Drug Profile 152
PEV-3 - Drug Profile 154
artesunate - Drug Profile 156
Sulfadoxine + Pyrimethamine - Drug Profile 158
Malarone - Drug Profile 159
Azithromycin + Sulfadoxine + Pyrimethamine - Drug Profile 160
Artesunate + Mefloquine - Drug Profile 162
Artekin - Drug Profile 163
NMRC-M3V-Ad-PfCA - Drug Profile 164
NMRC-MV-Ad-PfC + NMRC-MV-Ad-PfA - Drug Profile 166
Trimethoprim + Sulfamethoxazole - Drug Profile 168
Sulfadoxine + Pyrimethamine - Drug Profile 170
Dihydroartemisinin + Piperaquine - Drug Profile 172
Lopinavir + Ritonavir + Zidovudine + Lamivudine - Drug Profile 174
RTSS + AS02A - Drug Profile 176
RTSS + AS01B - Drug Profile 177
Mosquirix - Drug Profile 178
BKSE-36 - Drug Profile 180
EBA-175 RII-NG Malaria Vaccine - Drug Profile 181
Amodiaquine + Artesunate - Drug Profile 183
BSAM2/Alhydrogel + CPG 7909 - Drug Profile 184
Dihydroartemisinin + Piperaquine - Drug Profile 185
Sulfadoxine + Pyrimethamine + Amodiaquine - Drug Profile 187
Sulfadoxine + Pyrimethamine + Artesunate - Drug Profile 188
Sulfadoxine + Pyrimethamine + Piperaquine - Drug Profile 190
Sulfadoxine-Pyrimethamine + Artesunate - Drug Profile 192
Sulfalene-Pyrimethamine + Amodiaquine - Drug Profile 194
AdCh63 MSP1 + AdCh63 ME-TRAP + MVA MSP1 + MVA ME-TRAP - Drug Profile 195
Mefloquine + Artesunate - Drug Profile 197
AdCh63 MSP1 + MVA MSP1 - Drug Profile 198
Azithromycin + Sulphadoxine + Pyrimethamine - Drug Profile 199
AdCh63 AMA1 + MVA AMA1 - Drug Profile 201
AdCh63 AMA1 + AdCh63 MSP1 + MVA AMA1 + MVA MSP1 - Drug Profile 202
Amodiaquine + Selenium - Drug Profile 203
Amodiaquine + Vitamin A - Drug Profile 204
Amodiaquine + Vitamin E - Drug Profile 205
Amodiaquine + Zinc - Drug Profile 206
Artesunate + Selenium - Drug Profile 207
Artesunate + Vitamin A - Drug Profile 208
Artesunate + Vitamin E - Drug Profile 209
Artesunate + Zinc - Drug Profile 210
AMA1-C1 + Alhydrogel + CPG 7909 - Drug Profile 211
Artequin - Drug Profile 212
Ad35-CS - Drug Profile 213
artesunate - Drug Profile 214
Chloroquine - Drug Profile 215
Chloroquine - Drug Profile 217
Cotrimoxazole - Drug Profile 219
Cotrimoxazole - Drug Profile 220
Dihydroartemisinin + Piperaquine - Drug Profile 221
Sulfadoxine + Pyrimethamine - Drug Profile 222
Pfs25 Conjugate Vaccine - Drug Profile 223
Duocortexin - Drug Profile 225
PMX-70008 - Drug Profile 226
Malaria Vaccine - Drug Profile 227
Dihydroartemisinin + Piperaquine - Drug Profile 228
VMP001 + AS01B - Drug Profile 229
Malaria Vaccine - Drug Profile 231
Malaria Vaccine - Drug Profile 232
IMX-MSP3 - Drug Profile 233
IMX-MSP4 - Drug Profile 234
sevuparin sodium - Drug Profile 235
FALVAC-1A - Drug Profile 236
TMX-201 - Drug Profile 237
Pf-27 LSP - Drug Profile 238
Mefloquine + Artesunate - Drug Profile 239
AN-3661 - Drug Profile 240
Lm Malaria - Drug Profile 242
Malaria Vaccine - Drug Profile 243
MSP3-LSP/ALOH - Drug Profile 244
Nonadjuvanted Polypeptide Nanoparticle Vaccine - Drug Profile 246
DNA-Ad Vaccine + Adenovirus Type 5 Vaccine Boost - Drug Profile 247
NITD-609 - Drug Profile 248
SAPN Malaria Vaccine - Drug Profile 249
JVRS-100 + Malaria Vaccine - Drug Profile 250
RCQ Anti-Malaria Program - Drug Profile 251
Modified Acridone Anti-malaria Program - Drug Profile 252
Ad35-CS + RTS,S - Drug Profile 253
Scorpion Venom - Drug Profile 254
Manzamine - Drug Profile 255
Drug For Malaria - Drug Profile 256
Drug For Malaria - Drug Profile 257
ATML-147 - Drug Profile 258
BPH-703 - Drug Profile 259
Malaria NG Pf - Drug Profile 260
Malaria Vaccine - Drug Profile 261
Malaria Vaccine - Drug Profile 262
Xenomycin - Drug Profile 263
Fosmidomycin + Azithromycin - Drug Profile 264
Fosmidomycin + Clindamycin - Drug Profile 265
Carbohydrate Malaria Vaccine - Drug Profile 266
tSVP For Malaria - Drug Profile 267
Malaria Vaccine - Drug Profile 268
Cysteamine + Artemisinin - Drug Profile 269
CDRI-97/78 - Drug Profile 270
CDRI-99/411 - Drug Profile 271
Malaria Therapeutics – Drug Profile Updates 272
Malaria Therapeutics – Discontinued Products 279
Malaria Therapeutics - Dormant Products 282
Malaria – Product Development Milestones 292
Featured News & Press Releases 292
Appendix 300
Methodology 300
Coverage 300
Secondary Research 300
Primary Research 300
Expert Panel Validation 300
Contact Us 301
Disclaimer 301

List of Tables
Number of Products Under Development for Malaria, H2 2012 23
Products under Development for Malaria – Comparative Analysis, H2 2012 24
Number of Products under Development by Companies, H2 2012 26
Number of Products under Development by Companies, H2 2012 (Contd..1) 27
Number of Products under Development by Companies, H2 2012 (Contd..2) 28
Number of Products under Development by Companies, H2 2012 (Contd..3) 29
Number of Products under Investigation by Universities/Institutes, H2 2012 31
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 32
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 33
Comparative Analysis by Late Stage Development, H2 2012 34
Comparative Analysis by Mid Clinical Stage Development, H2 2012 35
Comparative Analysis by Early Clinical Stage Development, H2 2012 36
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 37
Products under Development by Companies, H2 2012 38
Products under Development by Companies, H2 2012 (Contd..1) 39
Products under Development by Companies, H2 2012 (Contd..2) 40
Products under Development by Companies, H2 2012 (Contd..3) 41
Products under Investigation by Universities/Institutes, H2 2012 42
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 43
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 44
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 45
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 46
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 47
Sanofi-Aventis, H2 2012 48
GlaxoSmithKline plc, H2 2012 49
Inovio Biomedical Corporation, H2 2012 50
GenVec, Inc., H2 2012 51
Merck & Co., Inc., H2 2012 52
Eastland Medical Systems Limited, H2 2012 53
Novartis AG, H2 2012 54
Actelion Ltd, H2 2012 55
Pfizer Inc., H2 2012 56
Ranbaxy Laboratories Limited, H2 2012 57
Aduro BioTech, H2 2012 58
CEL-SCI Corporation, H2 2012 59
Crucell N.V., H2 2012 60
Mymetics Corporation, H2 2012 61
Cleveland BioLabs, Inc., H2 2012 62
Patrys Limited, H2 2012 63
Alnylam Pharmaceuticals, Inc, H2 2012 64
IPCA Laboratories Limited, H2 2012 65
Lipoxen PLC, H2 2012 66
Raptor Pharmaceuticals Corp., H2 2012 67
PolyMedix, Inc., H2 2012 68
Affitech A/S, H2 2012 69
Colby Pharmaceutical Company, H2 2012 70
Avanti Therapeutics, H2 2012 71
Bharat Biotech International Limited, H2 2012 72
Jenrin Discovery, Inc., H2 2012 73
Mucosis B.V., H2 2012 74
Anacor Pharmaceuticals, Inc., H2 2012 75
Telormedix SA, H2 2012 76
Dilafor AB, H2 2012 77
Okairos, H2 2012 78
Sanaria Inc., H2 2012 79
NovaLead Pharma Pvt. Ltd., H2 2012 80
Acetylon Pharmaceuticals, Inc., H2 2012 81
Etubics Corporation, H2 2012 82
iBio, Inc., H2 2012 83
PepTcell Limited, H2 2012 84
Genocea Biosciences, Inc., H2 2012 85
PALUMED S.A., H2 2012 86
Sigma-Tau Pharmaceuticals, Inc., H2 2012 87
Selecta Biosciences, Inc., H2 2012 88
Pfenex Inc., H2 2012 89
VLP Biotech, Inc., H2 2012 90
Jomaa Pharma GmbH, H2 2012 91
Assessment by Monotherapy Products, H2 2012 92
Assessment by Combination Products, H2 2012 93
Assessment by Stage and Route of Administration, H2 2012 95
Assessment by Stage and Molecule Type, H2 2012 98
Malaria Therapeutics – Drug Profile Updates 282
Malaria Therapeutics – Discontinued Products 289
Malaria Therapeutics – Discontinued Products (Contd..1) 290
Malaria Therapeutics – Discontinued Products (Contd..2) 291
Malaria Therapeutics – Dormant Products 292
Malaria Therapeutics – Dormant Products (Contd..1) 293
Malaria Therapeutics – Dormant Products (Contd..2) 294
Malaria Therapeutics – Dormant Products (Contd..3) 295
Malaria Therapeutics – Dormant Products (Contd..4) 296
Malaria Therapeutics – Dormant Products (Contd..5) 297
Malaria Therapeutics – Dormant Products (Contd..6) 298
Malaria Therapeutics – Dormant Products (Contd..7) 299
Malaria Therapeutics – Dormant Products (Contd..8) 300
Malaria Therapeutics – Dormant Products (Contd..9) 301

List of Figures
Number of Products under Development for Malaria, H2 2012 23
Products under Development for Malaria – Comparative Analysis, H2 2012 24
Products under Development by Companies, H2 2012 25
Products under Investigation by Universities/Institutes, H2 2012 30
Late Stage Products, H2 2012 34
Mid Clinical Stage Products, H2 2012 35
Early Clinical Stage Products, H2 2012 36
Discovery and Pre-Clinical Stage Products, H2 2012 37
Assessment by Monotherapy Products, H2 2012 92
Assessment by Combination Products, H2 2012 93
Assessment by Route of Administration, H2 2012 94
Assessment by Stage and Route of Administration, H2 2012 95
Assessment by Molecule Type, H2 2012 96
Assessment by Stage and Molecule Type, H2 2012 97

Customers who bought this item also bought

• Anemia - Pipeline Review, H2 2012
• Acute Pain - Pipeline Review, H2 2012
• Cervical Cancer - Pipeline Review, H2 2012
• Hypertension - Pipeline Review, H2 2012
• Influenza A Infections - Pipeline Review, H2 2012
• Lymphoma - Pipeline Review, H2 2012
• Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2012
• Bladder Cancer - Pipeline Review, H2 2012
• Allergies - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012